Tag Archives: Yaz Study

Current Yasmin and Yaz Label Warnings Are Inadequate

Posted on December 9, 2011 by Kristine Meredith

Seated around a U-shaped configuration of tables sat the 26 member FDA Advisory Committee — all scientists or physicians gathered to discuss the risks of birth control pills containing DRSP. They focused on the risks as described in recent studies, … Continue reading →

Posted in Yaz & the FDA | Tagged , , | Comments Off

New Dutch Study Shows Yaz has Greater VTE Risk

Posted on November 3, 2011 by Kristine Meredith

A Dutch research team has published a new study concluding that Yaz has a greater risk of causing blood clots than other birth control pills. The Dutch cohort study looked at over one million women from 2001-2008. Researchers confirmed nearly … Continue reading →

Posted in Yaz Science & Chemistry | Tagged , | Comments Off

More Evidence that Yaz carries an increased risk of VTE

Posted on October 28, 2011 by Kristine Meredith

  The FDA posted the results of its much anticipated large retrospective study about the risk of venous thrombotic events (VTEs) and  newer contraceptives containing drosperinone (DRSP)  such as Yasmin, Yaz and Beyaz. The FDA reports “In adjusted analyses, DRSP … Continue reading →

Posted in Yaz & the FDA | Tagged , | Comments Off

FDA Remains Inconclusive Regarding Drospirenone Study Results

Posted on September 29, 2011 by Kristine Meredith

The FDA has communicated a luke warm statement about the safety of birth control pills containing drospirenone, stating that it “has not yet reached a conclusion and remains concerned.” Consumers continue to await the final results of the FDA-funded study … Continue reading →

Posted in Yaz & the FDA | Tagged , | Comments Off

Yet Another Government Yaz Safety Investigation

Posted on July 27, 2011 by Dylan

Earlier we told you about the new investigation of Yaz and Yasmin by the Food and Drug Administration (FDA). Canada is now joining the United States and Europe in taking a closer look at drospirenone products such as the birth … Continue reading →

Posted in Yaz Marketing and Warnings | Tagged , | Comments Off

FDA Investigates Yaz Blood Clot Risks

Posted on July 7, 2011 by A.J. De Bartolomeo

It’s been more than five years since the The Food and Drug Administration (FDA) first warned that Bayer was exaggerating the benefits and minimizing the risks associated with the synthetic hormone drospirenone found in the leading birth control pills Yaz … Continue reading →

Posted in Yaz & the FDA | Tagged , , , | Comments Off

Yasmin Label Change in the European Union (EU)

Posted on April 6, 2010 by Mike Danko

On Friday, March 26, 2010, Bayer announced that it will update the Yasmin label in the European Union (EU). The new Yasmin label will include the results of four epidemiological studies (epidemiological studies are conducted to figure out what factors … Continue reading →

Posted in Yaz Marketing and Warnings, Yaz Side Effects | Tagged , , | Comments Off

Medical Studies Link Hormone in Yaz, Yasmin and Ocella to Increased Risk of Blood Clots

Posted on November 4, 2009 by Dylan

All birth control pills come with some risk, but what many people don’t know is that there is medical evidence showing that the hormone used in Yaz, Yasmin and Ocella known as drospirenone, or "drsp," substantially increases that risk. Earlier … Continue reading →

Posted in Yaz Side Effects | Tagged , , | Comments Off

Lost in Translation? Swiss Investigation into potential severe side-effects of Yaz

Posted on November 4, 2009 by Dylan

Yaz in the News: As reported by Bloomberg News, in late September 2009, Swissmedic, the Swiss regulatory authority for drugs and medical devices, began an investigation into Yaz after a woman died from a pulmonary embolism while taking the birth … Continue reading →

Posted in Yaz Side Effects | Tagged | Comments Off